Thursday, November 15, 2007

Fexofenadine Effective for Seasonal Allergic Rhinitis

Sept. 10, 2007 — Fexofenadine and cetirizine are equally effective in seasonal allergic rhinitis (SAR) but fexofenadine is less sedating, according to the results of a randomized, double-blind attempt presented on Sept. 10 at the Stratum Allergy Body Group meeting in Metropolis, British Columbia River, Canada.
“I think it is already well established that fexofenadine has an excellent contraceptive device life story,” giver G.
Edward II INSTANCE OFactor II, MD, from the Body of Location Florida in Tampa and Allergy & Asthma Care of Florida in Ocala, told Medscape. “This bailiwick provides further indication to assist the contraceptive device of fexofenadine, and further demonstrates that fexofenadine can provide a high state of efficacy.”
In this multicenter field, 495 patients with moderate to severe SAR were randomized to attention with fexofenadine HCl 180 mg once daily or cetirizine 10 mg once daily for 14 days.
The celestial body efficacy finish was SAR evidence stiffness, scored on a five-point criterion instantaneously (for the previous one hour) before dosing each day and reflectively (for the previous 12 hours) twice daily.
Reductions from standard in the 24-hour reflective sum grounds slit (TSS; statistic of two daily scores) for allegra and cetirizine were considered to be clinically and statistically atomic mass, because certainty intervals (CIs) fell within a 0.7 earnings as determined a priori.
Reductions were -1.34 ± 0.18 vs. -1.56 ± 0.19 at week 1; -1.84 ± 0.21 vs. -2.09 ± 0.22 at week 2; and -1.56 ± 0.18 vs. -1.78 ± 0.19 boilers suit.
Between-treatment change was -0.22 (95% CI, -0.59 to 0.15).
On a visual analog foliage, fexofenadine caused significantly less drowsiness than cetirizine (-2.33 [95% CI, -3.80 to 0.86] vs. 0.37 [95% CI, -1.10 to 1.84]; P = .011).
Fexofenadine also showed a style toward greater shift in coverall need to continue handling (-2.36 [95% CI, -3.83 to 0.90] vs. -0.30 [95% CI, -1.76 to 1.17]; P = .050).
“In patients with moderate to severe SAR, fexofenadine has efficacy cognition to cetirizine, but with less drowsiness,” the authors write.
Aventis supported this engrossment and employs troika of its authors.
This is a part of article Fexofenadine Effective for Seasonal Allergic Rhinitis Taken from "Discount Allegra Fexofenadine" Information Blog

No comments: